Efficacy of telaprevir-based therapy for difficult-to-treat patients with genotype 2 chronic hepatitis C in Japan-Reference-Cited by-同舟云学术

Efficacy of telaprevir-based therapy for difficult-to-treat patients with genotype 2 chronic hepatitis C in Japan

Published:2014-11-18 Issue:7 Volume:45 Page:745-754
ISSN:1386-6346
Container-title:Hepatology Research
language:en
Short-container-title:Hepatol Res

Author:

Kumada Hiromitsu¹,Sato Ken²,Takehara Tetsuo³,Nakamuta Makoto⁴,Ishigami Masatoshi⁵,Chayama Kazuaki⁶,Toyota Joji⁷,Suzuki Fumitaka¹,Nakayasu Yoshiyuki⁸,Ochi Miyoko⁸,Yamada Ichimaro⁸,Okanoue Takeshi⁹

Affiliation:

1. Department of Hepatology; Toranomon Hospital; Tokyo Japan

2. Department of Medicine and Molecular Science; Gunma University Graduate School of Medicine; Gunma Japan

3. Department of Gastroenterology and Hepatology; Osaka University Graduate School of Medicine; Osaka Japan

4. Department of Gastroenterology; Kyushu Medical Center; National Hospital Organization; Fukuoka Japan

5. Department of Gastroenterology and Hepatology; Nagoya University School of Medicine; Nagoya Japan

6. Department of Medical and Molecular Science; Division of Frontier Medical Science; Programs for Biomedical Research; Graduate School of Biomedical Science; Hiroshima University; Hiroshima Japan

7. Department of Gastroenterology; Sapporo Kosei General Hospital; Hokkaido Japan

8. Development Division; Mitsubishi Tanabe Pharma Corporation; Tokyo Japan

9. Department of Gastroenterology and Hepatology; Saiseikai Suita Hospital; Osaka Japan

Publisher

Wiley

Subject

Infectious Diseases,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/hepr.12416/fullpdf

Reference29 articles.

1. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence;Mohd Hanafiah;Hepatology,2013

2. Prognosis of chronic hepatitis C: results of a large, prospective cohort study;Niederau;Hepatology,1998

3. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin;Kenny-Walsh;N Engl J Med,1999

4. Hepatitis C therapy in non-genotype 1 patients: the near future;Wartelle-Bladou;J Viral Hepat,2012

5. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan;Kumada;J Hepatol,2012

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hepatitis C virus (HCV) : Development of anti-HCV agents and anti-HCV therapy;Okayama Igakkai Zasshi (Journal of Okayama Medical Association);2020-12-01

2. Cost-effectiveness analysis of sofosbuvir plus ribavirin in patients with genotype 2 chronic hepatitis C: an analysis with real world outcomes from a multicentre cohort in Japan;BMJ Open;2019-06

3. Eltrombopag enables initiation and completion of pegylated interferon/ribavirin therapy in Japanese HCV‑infected patients with chronic liver disease and thrombocytopenia;Experimental and Therapeutic Medicine;2019-05-24

4. Evidence-based cancer prevention recommendations for Japanese;Japanese Journal of Clinical Oncology;2018-04-12

5. Hepatocellular carcinoma or interferon-based therapy history attenuates sofosbuvir/ribavirin for Japanese genotype 2 hepatitis C virus;World Journal of Gastroenterology;2018-04-07